Results 61 to 70 of about 1,655 (156)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers [PDF]

, 2012
The serotonin-2A receptor (5-HT(2A)R) has been implicated in the pathogenesis of schizophrenia and related inhibitory gating and behavioral inhibition deficits of schizophrenia patients.
Geyer, M A, Kometer, M, Quednow, Boris B, Vollenweider, F X   +3 more
core   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Online drug user-led harm reduction in Hungary: a review of "Daath". [PDF]

, 2013
Harm reduction has been increasingly finding its way into public drug policies and healthcare practices worldwide, with successful intervention measures justifiably focussing on the highest-risk groups, such as injecting drug users.
Móró Levente,, Rácz, József
core   +2 more sources

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Novel Psychoactive Substances: : the pharmacology of stimulants and hallucinogens [PDF]

, 2016
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Clinical Pharmacology, on March 2016, available online at doi: : http://www.tandfonline.com/doi/full/10.1586/17512433.2016.1167597.There are increasing levels ...
Corkery JM, Daly M, Dargan PI, Fabrizio Schifano, Farrè M, G. Duccio Papanti, John M. Corkery, Laura Orsolini, Shulgin AT, Shulgin AT, Soussan C, Ujváry I   +11 more
core   +3 more sources

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775) [PDF]

, 2018
Lysergic acid diethylamide (LSD) is perhaps one of the best-known psychoactive substances and many structural modifications of this prototypical lysergamide have been investigated. Several lysergamides were recently encountered as “research chemicals” or
Abramson, Abramson, Araneda, Ashby, Babij, Blair, Brandt, Brandt, Brandt, Brandt, Canal, Chemel, Darmani, Darmani, Darmani, Dilly, Dursun, Forster, Fox, Gasser, Gerber, Gogerty, González-Maeso, Gudelsky, Halberstadt, Halberstadt, Halberstadt, Halberstadt, Halberstadt, Halberstadt, Heal, Hintzen, Hoffman, Hofmann, Isbell, Karst, Kim, Kleven, Kraehenmann, Krebs-Thomson, Li, Marona-Lewicka, Martel, Matsumoto, Nakahara, Newman-Tancredi, Nichols, Nichols, Nichols, Nichols, Pokorny, Preller, Rényi, Salmi, Schreiber, Serafine, Sheldrick, Sheldrick, Silva, Stoll, Strassman, Testa, Valle, Vetulani, Vickers, Vollenweider, Wacker, Watts   +67 more
core   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Flashbacks Through Time: Historical Development and Current Use of the Term “Flashback” in Psychedelic and Post‐Traumatic Stress Disorder Research

Psychiatric Research and Clinical Practice, EarlyView.
In psychiatry, the term flashback is widely recognized in relation to post‐traumatic stress disorder (PTSD) as well as in the characterization of post‐psychedelic experiences. Although it is now most commonly associated with PTSD, the term was originally introduced in the context of psychedelics.
Ricarda Evens
wiley   +1 more source